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There is an ineluctable trend in the treat-
ment of inflammatory bowel disease
(IBD) towards an extensive use of immu-
nosuppressive drugs. These agents are
prescribed earlier in the disease,1 in an
increased proportion of patients (reaching
one-third in some European countries2)
and for prolonged periods since their
impact on the disease course is unfortu-
nately only suspensive.3 As a consequence,
clinicians have less to do with the well-
known direct complications of IBD, but
there are growing preoccupations
regarding established or uncertain safety
concerns related to immunosuppressive
treatment. IBD specialists are living in
slow motion the cultural revolution
brutally experienced by HIV specialists
with the arrival of efficient combined
antiviral treatment: these clinicians had to
turn from infectious disease specialists
into experts in drug management (obser-
vance, viral resistance) and drug compli-
cations (lipodystrophy, cardiovascular
problems).
Immunosuppressive drugs for IBD can
be deleterious through direct toxicity on
organs, and promotion of serious infec-
tions or cancers. Regarding the liver, direct
toxicity of anti-tumour necrosis factor
(TNF) appears anecdotal4 and that of
methotrexate well circumscribed and
largely preventable through the experience
of rheumatologists.5 Direct liver toxicity
of thiopurines is more problematic, repre-
senting the most frequent cause of liver
injury, together with fatty liver disease, in
tertiary care IBD centres.6 Concordant
data suggest that the prevalence and
annual incidence of 6-mercaptopurine-
and azathioprine-induced hepatotoxicity
are low (3% and 1.4%, respectively)7), and
that dose adaptation is most cases is
sufficient to resolve the problem.6 8
However, a safety signal of thiopurine-
induced injury of endothelial cells, essen-
tially nodular regenerative hyperplasia,
came from the use of 6-thioguanine.9
Nodular regenerative hyperplasia was
found thereafter in the French experience
to constitute a non-exceptional long-term
complication of treatment with thio-
purines, particularly in males with
previous extensive resection of the small
bowel, leading in some cases to irreversible
portal hypertension.10 11 Although the
reality and the extent of this risk are still
a matter of debate in other parts of the
world, efforts have to be made in the near
future to identify risk factors, clinical
symptoms (splenomegaly, portal hyper-
tension), biological surrogate markers
(drop in platelet count, acquired chole-
stasis), non-invasive detection tools
(MRI,12 transient elastography13) and
preventive measures (correction of folate
and vitamin B12 deficiency in patients
with malnutrition or previous small bowel
resection).11
Reactivation of hepatitis B and C under
immunosuppressive treatment also repre-
sents a clinically challenging situation,
even though concerning a minority of
patients of IBD. The first step in
addressing the problem is to identify
patients at risk when initiating immuno-
suppressive treatment. Regarding this
point, systematic hepatits B virus (HBV)
vaccination and serological testing before
introducing immunosuppressive treat-
ment have been recommended in the
ECCO (European Crohn’s and Colitis
Organisation) guidelines on opportunistic
infections, whereas no consensus could be
reached for hepatitis C Virus (HCV)
screening.14
The prevalence of patients with IBD at
risk for reactivation of hepatitis has been
clarified in a prospective cross-sectional
nationwide Spanish study.15 In this
country, the prevalence of patients with
IBD with hospital-based follow-up who
had biological markers of present and/or
past HBV or HCV infection was 9.7%,
a level similar to that of the local reference
general population and lower than in
previously published series. The authors
also pointed out the low prevalence (12%)
of patients with IBD with effective HBV
vaccination, and observed that transfusion
was no longer a significant risk factor for
HCV infection as soon as HCV markers
became mandatory in blood banks.
In this issue of Gut (see page 1340),
the same Spanish REPENTINA group
addressed the question of the prevalence
and risk factors for liver dysfunction (LD)
related to hepatitis B and C in patients
with IBD receiving immunosuppressive
treatment.16 They identified from the
previous study 104 patients with HBV
markers (25 hepatitis B surface antigen
(HBsAg) positive), 74 with HCV markers
(51 HCV RNA positive) and 16 patients
with markers of both infections, who
have been treated at some time with
immunosuppressive drugs. They retro-
spectively assessed in these patients the
frequency and severity of LD according to
exposure to one or more immunosup-
pressive drugs, with a median treatment
time of w1 year. The reader not familiar
with the hepatology literature has first to
be clear about consensual or adapted
definitions of liver abnormalities in order
to fully understand the results. According
to an international classification based on
biological tests alone,17 ‘abnormalities’ of
liver tests can been defined as an increase
in aspartate transaminase, alanine trans-
aminase (ALT), alkaline phosphatase (AP),
g-glutamyl transferase or total bilirubin
between N (upper limit of the normal
range) and 2N, whereas the terms ‘liver
injury ’ or ‘hepatotoxicity’ are proposed if
there is an increase of >2 in the afore-
mentioned liver tests. For the purpose of
the study of hepatitis B and C in IBD,
Loras et al proposed specific definitions for
characterising three kinds of LD: viral
reactivation or replication, acute liver
failure and fulminant liver failure. For
HBV, reactivation was defined as an
increase of 1.5- to 2-fold compared with
the baseline value of ALT plus an increase
of >2000 IU/ml HBV DNA levels or DNA
reappearance in a negative patient. HCV
replication was defined as a significant
increase in RNC-HCV or RNA reappear-
ance in a negative patient plus an increase
of 1.5- to 2-fold compared with the base-
line value. LD related to immunosuppres-
sive treatment in a HCV-infected patient
was defined as a significant increase of
ALT or HCV RNA virus load. Acute liver
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failure was defined as a sudden and severe
impairment of liver function (bilirubin
>2 mg/dl, albumin <34 g/l or
prothrombin time <50%) and fulminant
liver failure as severe acute failure
complicated by hepatic encephalopathy.
The authors observed that 36, 24 and 0%
of the 25HBsAg-positive patients developed
LD,hepatic failure or fulminant liver failure,
respectively. Remarkably and unfortu-
nately, only 6 of these 25 patients had
received antiviral treatment before immu-
nosuppression. No reactivation was found
in antihepaptitis B core antigen (HBc)-
positive patients lacking HBsAg. Regarding
HCV, viral reactivationwasobserved inonly
16% of the 51 HCV RNA-positive patients,
with one hepatic failure. To be treated with
$2 immunosuppressive drugs (including
steroids) was an independent predictor for
HBV reactivation (OR 8.6). Of note, no
reactivation was observed in patients
receiving a monotherapy with azathioprine
or infliximab together with a preventive
antiviral treatment against HBV, and all the
cases of liver failure occurred in patients
receiving steroids alone or in combination
with azathioprine or infliximab. No signifi-
cant rate of progression towards cirrhosis
was observed in either HBV or HCV infec-
tion. In summary, these original data are
reassuring when considering initiating
immunosuppressive drugs in HCV-infected
patients. The same is true for HBV-infected
patients receiving antiviral preventive
treatment planned to be treated with
a monotherapy by azathioprine or inflix-
imab, but without additional steroids.
Most data on HBV under immunosup-
pression had been collected previously in
patients receiving chemotherapy for
haemotologicalmalignancies. A greatmerit
of the Spanish study is the presentation of
novel, valuable data on the effects of
immunosuppression for IBD. Interestingly,
the results seem to confirm the recom-
mendations given by hepatological associ-
ations, based mainly on HBV reactivation
with chemotherapy: recent practice guide-
lines by the AASLD (American Association
for the Study of Liver Diseases) and EASL
(European Association for the Study of the
Liver) and the German S3 guidelines
recommend prophylactic antiviral treat-
ment for hepatitis B carriers and agree that
routine prophylaxis is not indicated for
HBsAg-negative, but anti-HBc-positive
patients.18e20
This Spanish cooperative study is also
emblematic of a modern methodological
approach for addressing safety concerns
in very specific subgroups of patients.
Premarketing clinical trials, postmarketing
reporting and huge population-based
cohorts without access to detailed indi-
vidual stories are not able to provide this
information. In contrast, cooperative
cohorts adequately tailored for addressing
pre-established questions have reasonable
chances to successfully address some
‘orphean’ clinically relevant interrogations,
and must be encouraged.
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